

# Cryopyrin-Associated Periodic Syndrome (CAPS) - Pipeline Insight, 2021

<https://marketpublishers.com/r/C2D93BB04000EN.html>

Date: July 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: C2D93BB04000EN

## Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Cryopyrin-Associated Periodic Syndrome (CAPS) - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Cryopyrin-Associated Periodic Syndrome (CAPS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Cryopyrin-Associated Periodic Syndrome (CAPS) Understanding

#### Cryopyrin-Associated Periodic Syndrome (CAPS): Overview

Cryopyrin-associated periodic syndrome or syndromes (CAPS), also known as cryopyrinopathies, are genetic autoinflammatory syndromes defined by 'gain-of-function' mutations affecting the cryopyrin protein. Cryopyrin-associated periodic syndromes are all autosomal dominant genetic conditions, meaning only one copy of the abnormal gene is required to develop the clinical syndrome. CAPS comprises 3 disorders on a continuum of severity: severe CINCA syndrome, intermediate Muckle-Wells syndrome (MWS) and milder familial cold urticaria (FCAS).

'Cryopyrin-Associated Periodic Syndrome (CAPS) - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cryopyrin-Associated Periodic Syndrome (CAPS) pipeline landscape is provided which includes the disease overview and Cryopyrin-Associated Periodic Syndrome (CAPS) treatment guidelines. The assessment part of the report embraces, in depth Cryopyrin-Associated Periodic Syndrome (CAPS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cryopyrin-Associated Periodic Syndrome (CAPS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cryopyrin-Associated Periodic Syndrome (CAPS) R&D. The therapies under development are focused on novel approaches to treat/improve Cryopyrin-Associated Periodic Syndrome (CAPS).

## Cryopyrin-Associated Periodic Syndrome (CAPS) Emerging Drugs Chapters

This segment of the Cryopyrin-Associated Periodic Syndrome (CAPS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Cryopyrin-Associated Periodic Syndrome (CAPS) Emerging Drugs

### DFV 890: Novartis

DFV 890 is a NLRP3 protein inhibitor being developed by Novartis. Currently, it is in Phase II stage of development to treat Cryopyrin-associated periodic syndromes.

### IZD334: Inflazome

IZD334 is a NLRP3 protein inhibitors. Activated NLRP3 acts as a 'danger sensor' in the body to release the pro-inflammatory cytokines IL-1 $\beta$ , IL-18 and induce uncontrolled, lytic cell death (pyroptosis). These processes lead to chronic inflammation, and as such, NLRP3 has been implicated in a large number of diseases. Acquisition of Inflazome had given Roche full rights to the Inflazome portfolio.

Further product details are provided in the report.....

### Cryopyrin-Associated Periodic Syndrome (CAPS): Therapeutic Assessment

This segment of the report provides insights about the different Cryopyrin-Associated Periodic Syndrome (CAPS) drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Cryopyrin-Associated Periodic Syndrome (CAPS)

There are approx. 3+ key companies which are developing the therapies for Cryopyrin-Associated Periodic Syndrome (CAPS). The companies which have their Cryopyrin-Associated Periodic Syndrome (CAPS) drug candidates in the most advanced stage, i.e. phase II include, Novartis.

#### Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Cryopyrin-Associated Periodic Syndrome (CAPS) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cryopyrin-Associated Periodic Syndrome (CAPS): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cryopyrin-Associated Periodic Syndrome (CAPS) therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cryopyrin-Associated Periodic Syndrome (CAPS) drugs.

### Cryopyrin-Associated Periodic Syndrome (CAPS) Report Insights

- Cryopyrin-Associated Periodic Syndrome (CAPS) Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

### Cryopyrin-Associated Periodic Syndrome (CAPS) Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

### Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Cryopyrin-Associated Periodic Syndrome

(CAPS) drugs?

How many Cryopyrin-Associated Periodic Syndrome (CAPS) drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cryopyrin-Associated Periodic Syndrome (CAPS) therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Cryopyrin-Associated Periodic Syndrome (CAPS) and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Novartis

Inflazome

Mabpharm

Roche

## Key Products

DFV 890

IZD 334

Inzomelid

CMAB 816

## Contents

Introduction

Executive Summary

Cryopyrin-Associated Periodic Syndrome (CAPS): Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Mid Stage Products (Phase II)

Comparative Analysis

DFV 890: Novartis

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

IZD 334: Inflazome

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Cryopyrin-Associated Periodic Syndrome (CAPS) Key Companies

Cryopyrin-Associated Periodic Syndrome (CAPS) Key Products

Cryopyrin-Associated Periodic Syndrome (CAPS)- Unmet Needs

Cryopyrin-Associated Periodic Syndrome (CAPS)- Market Drivers and Barriers



Cryopyrin-Associated Periodic Syndrome (CAPS)- Future Perspectives and Conclusion  
Cryopyrin-Associated Periodic Syndrome (CAPS) Analyst Views  
Cryopyrin-Associated Periodic Syndrome (CAPS) Key Companies  
Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Cryopyrin-Associated Periodic Syndrome (CAPS)

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Cryopyrin-Associated Periodic Syndrome (CAPS)

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Cryopyrin-Associated Periodic Syndrome (CAPS) - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/C2D93BB04000EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C2D93BB04000EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970